Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
